AbbVie Pummeled After Delivering A Fourth-Quarter Beat — On The Back Of Humira

Group 1 - AbbVie reported adjusted earnings of $2.71 per share on $16.62 billion in fourth-quarter sales, surpassing analyst expectations of $2.65 per share and $16.41 billion in sales [1] - The company's earnings per share increased from $2.16 in the same period last year, while sales rose from $15.1 billion [1] - AbbVie's immunology products, Rinvoq and Skyrizi, continue to drive growth, contributing to a strong performance despite the stock slump [1] Group 2 - The stock of AbbVie experienced a decline early Wednesday despite the positive earnings report and guidance [1] - Analysts had anticipated a better market reaction given the earnings beat, indicating potential market volatility or investor sentiment issues [1] - The overall market context included a surge in the Russell 2000 index, highlighting a mixed performance among small-cap stocks [1]